Clinical Pearls
Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.
- The TRINOVA-1 trial studied trebananib plus paclitaxel versus placebo plus paclitaxel in 919 patients who had recurrent ovarian cancer and up to three prior lines of therapy
- Trebananib plus weekly paclitaxel improved the hazard ratio for progression by 0.66
- The combination also improved response rate and the survival data, although not yet mature, showed a hazard ratio of 0.86